Therefore, through analysis of the TIC proportions in ccRCC patients, it is suggested that CASP4 may be involved in the maintenance and regulation of immune activity in the TME, which could provide new therapeutic targets and insights for the development of effective ccRCC immunotherapies. This evidence concerns the gene CASP4 and nonpapillary renal cell carcinoma.